HK1117141A1 - Process for the preparation of a new crystalline atorvastatin hemicalcium salt polymorph form - Google Patents

Process for the preparation of a new crystalline atorvastatin hemicalcium salt polymorph form

Info

Publication number
HK1117141A1
HK1117141A1 HK08105767.2A HK08105767A HK1117141A1 HK 1117141 A1 HK1117141 A1 HK 1117141A1 HK 08105767 A HK08105767 A HK 08105767A HK 1117141 A1 HK1117141 A1 HK 1117141A1
Authority
HK
Hong Kong
Prior art keywords
preparation
polymorph form
new crystalline
hemicalcium salt
crystalline atorvastatin
Prior art date
Application number
HK08105767.2A
Other languages
English (en)
Chinese (zh)
Inventor
Jozsef Barkczy
Nagy Pter Ktay
Gyula Simig
Zsuzsanna Szent-Kirllyi
Ferenc Bartha
Zoltn Katona
Donth Gyorgyi Vereczkeyn
Klmn Nagy
Norbert Nemeth
Gyrgy Ruzsics
Judit Cselenyak
Original Assignee
Egis Gygyszergyr Nyilvnosan Mkd Rszvnytrsasg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from HU0500370A external-priority patent/HU0500370D0/hu
Priority claimed from HU0600120A external-priority patent/HUP0600120A3/hu
Application filed by Egis Gygyszergyr Nyilvnosan Mkd Rszvnytrsasg filed Critical Egis Gygyszergyr Nyilvnosan Mkd Rszvnytrsasg
Publication of HK1117141A1 publication Critical patent/HK1117141A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
HK08105767.2A 2005-04-08 2008-05-23 Process for the preparation of a new crystalline atorvastatin hemicalcium salt polymorph form HK1117141A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HU0500370A HU0500370D0 (en) 2005-04-08 2005-04-08 New crystalline atorvastatin hemicalcium polimorph
HU0600120A HUP0600120A3 (en) 2006-02-14 2006-02-14 New crystalline atorvastatin hemicalcium, pharmaceutical composition containing it and process for producing it
PCT/HU2006/000026 WO2006106372A1 (en) 2005-04-08 2006-04-07 New crystalline atorvastatin hemicalcium salt polymorph form

Publications (1)

Publication Number Publication Date
HK1117141A1 true HK1117141A1 (en) 2009-01-09

Family

ID=89986585

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08105767.2A HK1117141A1 (en) 2005-04-08 2008-05-23 Process for the preparation of a new crystalline atorvastatin hemicalcium salt polymorph form

Country Status (13)

Country Link
US (1) US20090215855A1 (ro)
EP (1) EP1868993B1 (ro)
JP (1) JP5523699B2 (ro)
BG (1) BG66035B1 (ro)
CZ (1) CZ2007772A3 (ro)
EA (1) EA014079B1 (ro)
HK (1) HK1117141A1 (ro)
IL (1) IL186499A (ro)
NO (1) NO20075721L (ro)
RO (1) RO123642B1 (ro)
RU (1) RU2409563C2 (ro)
SK (1) SK288276B6 (ro)
WO (1) WO2006106372A1 (ro)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0610344A2 (pt) 2005-12-13 2016-11-29 Teva Pharma forma cristalizada do atorvastatin hemi-calcium, processo para sua preparação, produto famacêutico derivado e seu uso medicinal
AU2007219107B2 (en) * 2006-02-22 2012-12-06 Mylan Laboratories Ltd. New crystalline form of Atorvastatin hemi-calcium
EP2522348B1 (en) * 2009-12-25 2016-05-25 Sawai Pharmaceutical Co., Ltd. Atorvastatin-containing coated preparation
KR20120011249A (ko) * 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5003080A (en) * 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5298627A (en) * 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
DE69616808T2 (de) * 1995-07-17 2002-05-29 Warner Lambert Co Kristallines (r-(r*,r*))-2-(4-fluorphenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrol-1-heptancarbonsäure hemi calcium salz (atorvastatin)
MXPA03003900A (es) * 2000-11-03 2005-02-17 Teva Pharma Forma vii de hemicalcio de atorvastatina.
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
CA2622477A1 (en) * 2000-12-27 2002-07-04 Teva Pharmaceutical Industries Ltd. Crystalline forms of atorvastatin
DE03713610T1 (de) * 2002-02-15 2005-10-20 Teva Pharma Neue kristallformen von atorvastatin-hemicalcium und verfahren zu deren herstellung, sowie neue verfahren zur herstellung der formen i, viii und ix von atorvastatin-hemicalcium
KR20090045420A (ko) * 2002-02-19 2009-05-07 테바 파마슈티컬 인더스트리즈 리미티드 아토르바스타틴 헤미-칼슘 용매화합물의 탈용매화

Also Published As

Publication number Publication date
SK51252007A3 (sk) 2008-07-07
RO200700700A8 (ro) 2015-07-30
BG66035B1 (bg) 2010-11-30
NO20075721L (no) 2008-01-04
WO2006106372A8 (en) 2008-03-13
IL186499A (en) 2016-04-21
EP1868993A1 (en) 2007-12-26
US20090215855A1 (en) 2009-08-27
EA200702191A1 (ru) 2008-04-28
CZ2007772A3 (cs) 2008-02-27
RU2409563C2 (ru) 2011-01-20
SK288276B6 (sk) 2015-06-02
EP1868993B1 (en) 2014-04-30
IL186499A0 (en) 2008-01-20
JP5523699B2 (ja) 2014-06-18
EA014079B1 (ru) 2010-08-30
BG109992A (bg) 2008-05-30
RO123642B1 (ro) 2015-07-30
WO2006106372A1 (en) 2006-10-12
JP2008534669A (ja) 2008-08-28
RU2007140797A (ru) 2009-05-20

Similar Documents

Publication Publication Date Title
HK1123682A1 (en) Process for preparing a synthetic intermediate for preparation of branched nucleosides
ZA200708071B (en) Crystalline form of a quinolinone-carboxamide compound
IL185419A0 (en) Improved process for the synthesis of enantiomeric indanylamine derivatives
IL192362A0 (en) Processes for preparing intermediate compounds useful for the preparation of ezetimibe
IL185470A0 (en) Novel salt of quinuclidine derivative
IL181868A0 (en) Process for preparing forms of atorvastatin calcium substantially free of impurities
IL184715A0 (en) Process for the preparation of intermediates
PL1926732T3 (pl) Sposób wytwarzania związków karbapenemu
EP1945614A4 (en) PROCESS FOR THE PREPARATION OF AMLODIPINE CHIRAL GENTISATE
HK1117141A1 (en) Process for the preparation of a new crystalline atorvastatin hemicalcium salt polymorph form
WO2007099552A3 (en) Novel crystalline form of atovastatin hemi-magnesium
ZA200701016B (en) Process for the preparation of isothiazole derivatives
HK1105968A1 (en) Process for production of 3-alkenylcephem compounds 3-
IL186294A0 (en) A process for the preparation of phenyltetrazole compounds
IL191919A0 (en) Process for preparing a crystalline form of atorvastatin hemi-calcium
ZA200900208B (en) Xinafoate salt of a substituted 5-oxazol-2-yl-quinoline compound
EP1853558A4 (en) PROCESS FOR THE PRODUCTION OF ATORVASTATIN HEMICALCIUM
IL187981A0 (en) Crystalline forms of a pyrrolotriazine compound
PT1937662E (pt) Processo para a preparação de duloxetina
EP1858844A4 (en) NEW CRYSTALLINE FORMS OF ANTIDIABETIC COMPOUNDS
EP1986997A4 (en) NEW CRYSTALLINE HEMI-CALCIUM FORM OF ATORVASTATIN
IL195061A0 (en) Crystalline forms of atorvastatin
GB0506967D0 (en) Novel crystalline salt
HK1125101A1 (en) Solid salt forms of a pyrrole substituted 2-indolinone
GB0525710D0 (en) An improved process for preparing of substituted 2-benzimidazolesulfoxide compounds

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20180407